Randomized phase II study of atrasentan
โ
M. Dror Michaelson; Donald S. Kaufman; Philip Kantoff; William K. Oh; Matthew R.
๐
Article
๐
2006
๐
John Wiley and Sons
๐
English
โ 118 KB
๐ 2 views
## Abstract ## BACKGROUND. Metastatic prostate cancer is characterized by the presence of osteoblastic bone metastases. Bone metastases account for most of the morbidity from this disease. Inhibition of osteoclast activity with the potent bisphosphonate zoledronic acid reduces skeletal complicatio